[Skip to Navigation]
Views 1,779
Citations 0
Editorial
January 26, 2022

Challenges in the Design, Registration, and Reporting of Noninferiority Trials

Author Affiliations
  • 1Department of Clinical Epidemiology, Leiden University Medical Center (LUMC), Leiden, the Netherlands
  • 2Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, the Netherlands
JAMA Psychiatry. 2022;79(3):191-192. doi:10.1001/jamapsychiatry.2021.3932

In superiority trials, usually researchers expect that the treatment of interest is more effective (superior) compared with placebo or an active comparator treatment. To demonstrate superiority, a null hypothesis is defined that usually states that the outcomes are the same in the treatment arms. Convincing evidence against that hypothesis (often based on a P value that is less than a predefined threshold, eg, .05) would lead researchers to reject the null hypothesis and thus conclude that one treatment is better than the other. Therefore, in a superiority trial that provides convincing evidence that an experimental treatment is superior to placebo (or active comparator), conclusions about (relative) efficacy can be drawn.

Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×